Search

Skip to main content Accessibility help

Only show content I have access to (1)

Only show open access (1)

Articles (1)

Over 3 years (1)

From year:

To year:

Apply

Psychiatric Bulletin (1)

1 results

Losing participants before the trial ends erodes credibility of findings
Jun Xia, Clive Adams, Nishant Bhagat, Vinaya Bhagat, Paranthaman Bhoopathi, Hany El-Sayeh, Vanessa Pinfold, Yahya Takriti
Journal:

Psychiatric Bulletin / Volume 33 / Issue 7 / July 2009

Published online by Cambridge University Press:

02 January 2018, pp. 254-257

Print publication:

July 2009
- Article
- - You have access
  - Open access
- PDF
- HTML
- Export citation
Aims and Method
To estimate the proportion of attrition at which results of drug trials for people with schizophrenia lose enough credibility to become mistrusted by relevant groups of stakeholders. A piloted questionnaire was sent to 128 local clinicians, 100 relevant researchers and 104 service users and carers.
Results
We received the biggest number of responses from the service user and carer group (n=81, 76%); 43% of clinicians and 32% of researchers responded. All three groups suggested that the follow-up rate for a 12-week schizophrenia drug trial should be around 70–75% for the trial to be credible.
Clinical Implications
This survey suggests that relevant stakeholders, including researchers, fundamentally mistrust results of the majority of drug trials in schizophrenia. Adopting a more pragmatic trial design can help address this.